CD274 and non-small cell lung carcinoma: As shown in Fig. 4c, we generated new results in this research and reasonably deduced that mutation of ARID1A or ARID1B leads to changes in the expression levels of related proteins, which results in the poor prognosis of NSCLC on the one hand but enhances the sensitivity to ICI treatment in advanced NSCLC through elevating the TMB, enhancing PD-L1 expression and modulating the anticancer immune reaction on the other hand.